Onzima Ventures Share Discussion Threads

[fido] 26/7/2016 10:20

RAMPER.
LISTEN CAREFULLY

THERE ARE NO REVENUES.

Only in your wildest dreams.

[wahlberg] 26/7/2016 07:47

Looking forward to further patent news - each one additional confirmation and security of the longevity of revenues.

What pleases me is the timeframe to those huge revenues is so short for n4 compared to drug discovery companies.

Basically this means this stock is hoing to grow and grow in value over a period of years.

[wahlberg] 26/7/2016 07:41

£30-60m annual royalties for the Viagra drug alone of course.

In London today. So you're a taxi driver now having failed at investing and consultancy then? Haha

[patientcapital] 26/7/2016 07:40

"Reformulation is the key to creating value for off patent and soon to be off patent drugs and having access to the level of expertise in Opal gives us a huge advantage in this space. Not only do we have the exclusive rights to the most effective way to manufacture co-crystals we will now own the patents for a range of drugs that can be made using either Cocrys(R) or combinations of other available reformulation technologies."

[fido] 26/7/2016 06:19

RAMPER,
What revenues are those then, is it the ZERO revenues before it goes bust.
I was dropping someone off at the airport when I posted early hours, what`s your excuse for posting at 04.41 hrs.

Must read

[wahlberg] 26/7/2016 04:41

Yes, significantly higher upside here and in a short timeframe

Sit back and this stock will appreciate to 5p,10p+ and that's before the revenues hit

[bigego] 25/7/2016 23:07

Shame you did not read this

hxxp://www.shareprophets.com/views/15231/red-flags-at-night-ultima-networks-interims-when-s-the-placing

It was the market though, ten thousand ramping posts all excused by 'it was the market

[bigego] 25/7/2016 22:54

Well you are sending me asleep.

Sleep well darling..

Keep dreaming.

[bigego] 25/7/2016 22:51

Took you nine months to work out Gavin Burnell had history of success and failure.

Sharp tool you are not.

Tool of the highest order.

[bigego] 25/7/2016 22:47

Davey, is it special brew or white lightening the fuel of choice tonight?

[bigego] 25/7/2016 22:34

The booze fueled night time rant's just started.

[fido] 25/7/2016 22:26

Yet another of your CEO`s dissasters.
He`s been involved in a few of these.

Still, ONZ are the exception aren`t they, the one to make you all rich.
Doesn`t matter about all the other complete failures because ONZ is the one.

OR

It could just be that ONZ is just like all the rest and you are going to lose everything.

[bigego] 25/7/2016 21:19

Wahlbergs header post will be seen to fruition in the very near future;

wahlberg
17 Jul'16 - 08:41 5 0

Epic potential here. Once the big Pharma deals start to land (there will be several) and the upfront royalty payments (£3-5m) arrive, then the crowd will arrive.

10-20 products, annual royalties of £30-60m for Viagra alone. Wow.

I can see £10m mcap here in the short term, by the end of this year.

[bigego] 25/7/2016 21:18

PC this one sits at £11m mcap but achieved £26m not many months ago, looks very limited, all on POTENTIAL.

vgen Pharma (EVG) chief executive Stephen Franklin
6th July 2016


Can a humble molecule with a heritage in broccoli really cure any number of ailments?
That’s the premise behind Evgen Pharma and chief executive Stephen Franklin says that after thirteen years of development work, the company has arrived at the business end of proving it.
A phase II trial for the molecule, sulforaphane, as a treatment for a rare form of stroke has just got underway, while the company also has the funds for a breast cancer trial.
Results due in 2018 and Franklin says all investors have to do until then is hold their nerve.

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions
hxxp://evgen.com/

[bigego] 25/7/2016 20:52

Reached £50m on no revenues only potential? Whatever next, maybe their board needs Davey to calm them down...

[patientcapital] 25/7/2016 20:45

There's a small biotech plc called Optibiotics which has done little else other than file patents since it came to Aim. It has already ten bagged and guess what the revenue figures are?Zero.Hasn't stopped the mcap topping £50m at times.Best bit is, IMO, onz has more potential.